Price T Rowe Associates Inc. MD Purchases 676,771 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Price T Rowe Associates Inc. MD grew its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 23.5% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,557,136 shares of the biopharmaceutical company's stock after acquiring an additional 676,771 shares during the period. Price T Rowe Associates Inc. MD owned 5.36% of Celldex Therapeutics worth $89,890,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. EverSource Wealth Advisors LLC grew its holdings in Celldex Therapeutics by 215.7% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company's stock valued at $32,000 after purchasing an additional 878 shares during the last quarter. Headlands Technologies LLC acquired a new position in Celldex Therapeutics in the 4th quarter valued at $81,000. KBC Group NV raised its holdings in Celldex Therapeutics by 79.1% in the 4th quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company's stock worth $94,000 after acquiring an additional 1,647 shares during the period. AlphaQuest LLC lifted its position in Celldex Therapeutics by 171.0% during the 4th quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company's stock worth $108,000 after acquiring an additional 2,705 shares during the last quarter. Finally, Aristides Capital LLC bought a new stake in Celldex Therapeutics during the fourth quarter valued at about $202,000.

Celldex Therapeutics Trading Down 0.2 %

NASDAQ:CLDX traded down $0.05 during mid-day trading on Friday, hitting $20.66. The company's stock had a trading volume of 598,699 shares, compared to its average volume of 884,988. The stock has a fifty day moving average of $19.09 and a 200-day moving average of $23.17. The company has a market capitalization of $1.37 billion, a price-to-earnings ratio of -8.04 and a beta of 1.59. Celldex Therapeutics, Inc. has a fifty-two week low of $14.40 and a fifty-two week high of $47.00.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last issued its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.73) by $0.02. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. The business had revenue of $1.18 million during the quarter, compared to analysts' expectations of $1.25 million. On average, equities analysts anticipate that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

CLDX has been the topic of a number of recent analyst reports. Cantor Fitzgerald reiterated an "overweight" rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a research note on Wednesday, January 29th. UBS Group assumed coverage on Celldex Therapeutics in a report on Thursday, February 13th. They set a "buy" rating and a $44.00 price target for the company. Canaccord Genuity Group assumed coverage on shares of Celldex Therapeutics in a research report on Monday, April 28th. They set a "buy" rating and a $64.00 target price on the stock. The Goldman Sachs Group cut their target price on shares of Celldex Therapeutics from $42.00 to $36.00 and set a "neutral" rating for the company in a research note on Monday, March 3rd. Finally, Morgan Stanley started coverage on shares of Celldex Therapeutics in a research report on Thursday, March 20th. They issued an "overweight" rating and a $46.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $55.30.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.